# Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

> **NCT04047628** · PHASE3 · RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 156 (estimated)

## Conditions studied

- Relapsing Multiple Sclerosis
- Relapsing Remitting Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis

## Interventions

- **PROCEDURE:** Autologous Hematopoietic Stem Cell Transplantation
- **BIOLOGICAL:** Best Available Therapy (BAT)

## Key facts

- **NCT ID:** NCT04047628
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-12-19
- **Primary completion:** 2026-10
- **Final completion:** 2029-10
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2026-01-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04047628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04047628, "Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04047628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*